Medtronic Inc. (MDT) recently launched a new TSRH 3Dx Spinal System, which is a hook, rod and screw system used in complex spinal procedures. The system offers two screws designed to address multiple pathologies. The Multi Planar Adjusting (MPA) Screw gives surgeons the flexibility of a variable angle posted screw for targeted, controlled correction maneuvers. The OSTEOGRIP Screw enhances bone fixation by incorporating a dual-lead thread pattern that reduces toggle at the bone-screw interface.

The new pedicle screw system has a unique technology that addresses multiple spinal pathologies, from degenerative disc disease to spinal deformity. The product offers an alternative to patients for spinal stabilization with fusion. It works for patients suffering from degenerative spinal conditions, deformity, or injury of the thoracic, lumbar, and sacral spine. The TSRH Spinal System also provides Chromaloy rods and a minimally invasive capability.

We think that the new product will be widely accepted by

...

Medtronic, Inc. (MDT) recently launched MASTERGRAFT Strip - a new, highly flexible ceramic scaffold used in combination with a patient’s own bone for fusing multiple levels of the posterolateral spine, in the U.S. The strip is used by surgeons for a variety of bone grafting procedures.   MASTERGRAFT Strip is primarily used when the spine loses stability or its natural shape. The product offers a continuous latticework for longer grafting procedures at the back of the spine. It also enables maximization of the bony surface area contact and allows for continuous bone growth over large bony gaps. MASTERGRAFT Strip is available in unique lengths that eliminate the requirement of multiple strip units for a long fusion.   MASTERGRAFT Strip’s unique features and ease of handling during implantation makes it a preferred choice for spine surgeons. We therefore expect the product to increase the Spinal and Biologics business

...

Medtronic Inc. (MDT) recently reported the first enrollment for its Attain Success trial. The trial evaluates implant success, complication rates and procedure times for the company’s Attain Family of left-heart leads and delivery systems portfolio which are already available in the market.  The Attain Success trial enrollment will have roughly 2,000 patients at 150 medical centers in 18 countries around the world. The company will analyze data at baseline, implant and three months post-implant. The study will also capture implant success and complication rates (up to three months), procedure times, handling feedback and physician survey data.  In addition, the Attain Success trial enrollment will have a sub-study that will assess final left-heart lead placement site. Patients enrolled in the test will have a cardiac resynchronization therapy-defibrillator (CRT) device implanted in them. Results from the test are expected in 30 months.  If successful, the Attain Success ...

For Immediate Release

Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

BSX Settles, Lowers Results

Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic

...

Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic Act by Guidant. The allegations were reported prior to Boston’s acquisition of Guidant in 2006. Boston has recorded the litigation expense in its third quarter of fiscal 2009 results and updated its income statement accordingly. The expense has lowered the company’s GAAP earnings per share by 19 cents into a loss per share of 6 cents in the third quarter of 2009. Adjusted figures remained unaffected by this charge. Boston has also lowered its full fiscal 2009 GAAP earnings per share guidance to a range of 23 to 28 cents, compared to its prior guidance of 43 to 48 cents. The company’s adjusted earnings per share guidance ...

Haemonetics Corporation (HAE) reported strong results for the second quarter of fiscal 2010. Earnings per share were 69 cents, beating the Zacks Consensus Estimate of 65 cents and the year-ago earnings of 58 cents. Sales Total revenues in the reported quarter were $157 million, increasing 8% year over year. Excluding a favorable foreign currency translation (FX), revenues increased 6% year over year. On a geographic basis, U.S. sales represented roughly 48% of total sales and increased 12.5% year over year. International sales increased 3.5% year over year. Plasma disposables revenues increased 19% year over year to $59 million. Growth can be attributed to higher global demand for plasma collections, higher pricing and implementation of several long-term contracts with customers in the reported quarter. Platelet disposables revenues increased 3% year over year to $37 million due to the company’s strong distribution network in different key markets....

ATS Medical, Inc. (ATSI) reported a third quarter 2009 net loss of 1 cent per share, in-line with the Zacks Consensus Estimate but better than the year-ago loss per share of 6 cents. Total revenues for the reported quarter were $18.8 million, increasing 17.3% year over year. Excluding an unfavorable foreign currency translation (FX), total revenues increased 19.4% year over year. Growth was broad-based across its major business segments. Heart valve therapy revenues increased 20.5% year over year to $14.2 million. In this segment, Mechanical valve revenues increased 10% year over year to $11.6 million. This was due to higher demand for the ATS Open Pivot Mechanical Heart Valve in Asia and success from the recent launch of the AP360 valve in Japan. Tissue valve revenues were $1.4 million, compared to $0.3 million in the year-ago quarter. Heart valve repair revenues increased 29% year over ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday October 22, 2009

DrStockPick.com Stock Report!

AQNM, RTN, PSFT, PWRM, MDT, CSRH, SLB, CVAT, BA

**************************************************************

RTN, Raytheon Co.

RTN designs, develops, manufactures, integrates, and supports technological products, services, and solutions for governmental and commercial customers in the United States and internationally.

RTN reported third quarter 2009 income from continuing operations of $499 million, up 14 percent compared to $437 million in the third quarter 2008. EPS from continuing operations for the third quarter 2009 was $1.25, up 24 percent compared to $1.01 in the third quarter 2008.

**************************************************************

PSFT, Powersafe Technology Corp., PSFT.PK

Powersafe Technology Corp.’s (Other OTC: PSFT.PK) Subsidiary Amplification

...

For Immediate Release

Chicago, IL – October 22, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Morgan Stanley (MS), Goldman Sachs (GS), St. Jude Medical, Inc. (STJ), Medtronic Inc. (MDT) and Boston Scientific Corporation (BSX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s AnalystBlog:

Morgan Stanley Finally Profits

Morgan Stanley (MS) reported third-quarter 2009 income of $498 million this morning or 38 cents per share, compared with a loss of $159 million or $1.37 per share in the prior quarter and an income of $7.7 billion, or $7.38 per

...

St. Jude Medical, Inc. (STJ) today reported financial results for the third quarter of 2009 before the market opened. Earnings per share came in at 59 cents, compared to the Zacks Consensus Estimate of 58 cents and the year-ago earnings of 54 cents. Sales Net sales in the reported quarter increased 7% year over year to approximately $1.2 billion. Excluding an unfavorable foreign exchange translation (FX), net sales increased 10% year over year. Growth was witnessed across all the business segments. However, the company’s domestic revenues were below expectation primarily due to lack of purchase of cardiac rhythm management (CRM) devices by roughly 50 hospitals in the U.S. In terms of business segments: CRM revenues increased 2% year over year to $690 million. Growth was led by higher demand for both implantable cardioverter defibrillator (ICD) and pacemaker. ICD revenues increased 2% year over year to ...